IP Library Granted Patent US 9,381,239
Granted Patent B2
US 9,381,239 · App. 14/252,043 · Granted Jul 5, 2016

VLPS derived from cells that do not express a viral matrix or core protein

Inventors: Gale Smith (Rockville, MD); Peter Pushko (Rockville, MD); Kutub Mahmood (Rockville, MD); Bin Zhou (Rockville, MD)
Assignee: Novavax, Inc.
A61K39/145C12N7/00A61K2039/5258C07K2319/00C12N2710/16723C12N2760/16123
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,381,239
App. No.
14/252,043
Granted
Jul 5, 2016
Kind
B2
Abstract

The present invention discloses novel influenza virus-like particles (VLPs) that contain chimeric proteins or influenza membrane proteins. The chimeric proteins are derived from fragments of influenza membrane proteins fused to heterologous proteins. The invention includes antigenic formulations and vaccines comprising VLPs of the invention as well as methods of making and administering VLPs to vertebrates, including methods of inducing immunity to infections, such as influenza.

Claims (21)

1. A virus-like particle (VLP) comprising a first influenza membrane protein and a second influenza membrane protein, wherein the first influenza membrane protein is a hemagglutinin (HA) protein and the second influenza membrane protein is a neuraminidase (NA) protein, wherein the VLP does not comprise any viral matrix or core protein, and wherein the VLP does not carry genetic information encoding proteins.

2. The VLP of claim 1 , further comprising at least one additional protein from an infectious agent.

3. The VLP of claim 1 , wherein the HA protein is derived from a seasonal influenza virus.

4. The VLP of claim 3 , wherein the seasonal influenza virus is a type A influenza virus.

5. The VLP of claim 3 , wherein the seasonal influenza virus is a type B influenza virus.

6. The VLP of claim 1 , wherein the HA is derived from an avian influenza virus.

7. The VLP of claim 6 , wherein the influenza virus is H5N1.

8. The VLP of claim 6 , wherein the influenza virus is H9N2.

9. The VLP of claim 1 , wherein at least one influenza membrane protein is a chimeric protein comprising the cytoplasmic tail of an influenza membrane protein.

10. The VLP of claim 9 , wherein the cytoplasmic tail of an influenza membrane protein is from a HA protein.

11. The VLP of claim 1 , wherein at least one influenza membrane protein is a chimeric protein comprising the transmembrane domain of an influenza membrane protein.

12. The VLP of claim 11 , wherein the transmembrane domain of an influenza membrane protein is from a HA protein.

13. The VLP of claim 1 , wherein the NA protein is derived from a seasonal influenza virus.

14. The VLP of claim 13 , wherein the seasonal influenza virus is a type A influenza virus.

15. The VLP of claim 13 , wherein the seasonal influenza virus is a type B influenza virus.

16. The VLP of claim 1 , wherein the NA protein is derived from an avian influenza virus.

17. The VLP of claim 16 , wherein the influenza virus is H5N1.

18. The VLP of claim 16 , wherein the influenza virus is H9N2.

19. The VLP of claim 2 , wherein the at least one additional protein from an infectious agent is a chimeric protein.

20. The VLP of claim 19 , wherein the chimeric protein comprises a cytoplasmic and/or transmembrane domain of an orthomyxovirus protein.

21. A virus-like particle (VLP) comprising influenza proteins, wherein the influenza proteins consist of an influenza hemagglutinin (HA) protein and a influenza neuraminidase (NA) protein, wherein the VLP does not comprise any viral matrix or core protein, and wherein the VLP does not carry genetic information encoding proteins.

Assignments (2)
SECURITY INTEREST Recorded Feb 25, 2026
From: NOVAVAX, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 074976/0089 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 9, 2015
From: SMITH, GALE; PUSHKO, PETER; MAHMOOD, KUTUB; ZHOU, BIN
To: NOVAVAX, INC.
Reel/Frame 034920/0608 →
Continuity (3)
Division 12127625 · May 27, 2008
Provisional Application 60940201 · May 25, 2007
Related Publication 20140234372A1 · Aug 21, 2014